Survival and quality of life of cholangiocarcinoma patients: A prospective study over a 4 year period

Journal of Gastrointestinal and Liver Diseases

Volumn 19, Issue 3, 2010, Pages 285-290

  Mihalache, Florentina ^a   Tantau, Marcel ^a   Diaconu, Brindusa ^a   Acalovschi, Monica ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Adjuvant chemotherapy; Biliary stents; Cholangiocarcinoma; Curative surgery; Quality of life; Survival; Tnm stages

Indexed keywords

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; ENDOSCOPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; QUALITY OF LIFE; STENT; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT SURGICAL PROCEDURES; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; DECOMPRESSION, SURGICAL; ENDOSCOPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PALLIATIVE CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; ROMANIA; STENTS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650190035     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-125.
2. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
3. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
4. Fayers PM, Aaronson NK, et al. The EORTC QLQ-C30 Scoring Manual (3rd Ed). European Organisation for Research and Treatment of Cancer. Brussels 2001.
5. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975; 140: 170-178.
6. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314.
7. Li SQ, Liang LJ, Hua YP, et al. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma. Chin Med J 2009; 122: 2286-2291
8. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48: 308-321.
9. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995; 75: 171-190.
10. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
11. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 Suppl 6: VII-9.
12. Kelley ST, Bloomston M, Serafini F, et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg 2004; 70: 743-748.
13. Abu-Hamda EM, Baron TH. Endoscopic management of cholangiocarcinoma. Semin Liver Dis 2004; 24: 165-175.
14. Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344: 1655-1660.
15. Yoon HG, Kang JH, Lee EJ, et al. Intraductal ultrasonography for the selection of self expandable metal stent in extrahepatic bile duct carcinoma. Korean J Gastroenterol 2006; 48(6):415-420
16. Khan SA, Miras A, Pelling M, et al. Cholangiocarcinoma and its management. Gut 2007; 56:1755-1756
17. Kaassis M, Boyer J, et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc 2003; 57: 178-182.
18. Gerhardt T, Milz S, Schepke M, et al. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol. 2006;12:5495-500.
19. Dumoulin FL, Gerhardt T, Fuchs S, et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc. 2003;57:860-867
20. Gao F, Bai Y, Ma SR, et al. Systematic review: photodynamic therapy for unresectable cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2010;17:125-31.
21. Ortner MA. Photodynamic therapy for cholangiocarcinoma: overview and new developments. Curr Opin Gastroenterol. 2009;25(5):472-6.
22. Ballinger AB, McHugh M, et al. Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut 1994; 35: 467-470.
23. Abraham NS, Barkun JS, et al. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc 2002; 56: 835-841.
24. Luman W, Cull A, et al. Quality of life in patients stented for malignant biliary obstructions. Eur J Gastroenterol Hepatol 1997; 9: 481-484.
25. García Sánchez MV, López Vallejos P et al.Biliopancreatic tumors: patient survival and quality of life after palliative treatment. Rev Esp Enferm Dig 2004; 96: 305-314.
26. Balkwill F, Osborne R, et al. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 1987; 11: 1229-1232.
27. Hellerstein MK, Meydani SN, et al. Interleukin-1 - induced anorexia in the rat. J Clin Invest 1989; 84: 228-235.
28. Owyang C, May D, et al. Trypsin suppression of pancreatic enzyme secretion, differential effect on cholecystokinin release and the enteropancreatic reflex. Gastroenterology 1986; 91: 637-643.
29. Pungpapong S, Kongkam P. Experience on endoscopic retrograde cholangiopancreatography at tertiary referral center in Thailand: risks and complications. J Med Assoc Thai 2005; 88: 238-246.
30. Smith AC, Dowsett JF et al. Randomised trial of endoscopic stenting versus sugical bypass in malignant low bile duct obstruction. Lancet 1994; 344: 1655-1660.
31. Aljiffry M, Walsh MJ, et al. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009; 15: 4240-4262.